A recent report reveals that weight loss drugs have led to a significant drop in sales for the food industry, amounting to £780 million annually. This shift is attributed to the increasing use of GLP-1 medications such as Wegovy and Mounjaro, which have transformed shopping behaviors across the country.
According to research by Worldpanel by Numerator, the number of households with at least one member using weight loss drugs has nearly tripled in just two years, reaching 1.9 million adults. The report indicates that 6.3% of British households now have a current user, a sharp increase from 4.1% in 2025 and 2.3% in 2024, with women representing 77% of users.
This sudden surge in drug use has had a significant impact on the grocery market, with households where at least one member is on an appetite suppressant drug purchasing nearly 300 fewer grocery items in the first year, resulting in a collective spending decrease of £780 million, equivalent to £418 per household.
Users of these drugs report experiencing reduced cravings, with a notable decline in consumption of chocolate by 75% and crisps by 72%, leading to implications for manufacturers. Conversely, there has been an increase in sales of mouthwash by 20% and chewing gum by 24% due to reported side effects like dry mouth and bad breath.
The trend is also influencing the restaurant industry, with 40% of users expressing a preference for smaller portion sizes on menus. Notable figures like celebrity chef Heston Blumenthal have raised concerns about the industry’s future, emphasizing the need for adaptation to changing consumer behaviors.
Chantel Kennaugh, head of public sector and nutrition at Worldpanel by Numerator, highlighted the rapid evolution of weight loss medications from a specialized treatment to a mainstream phenomenon. She noted that 68% of users now take GLP-1s specifically for weight loss, indicating a shift in consumer engagement with food and drink that is forcing businesses to adapt swiftly.
Nishita Pattni, a senior consultant at the firm, acknowledged the complexity of the situation, with concerns about the rapid adoption of GLP-1 medications despite ongoing growth. As these drugs reshape consumer needs, retailers and manufacturers are expected to provide enhanced support and guidance to meet evolving demands.
